CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor types. SUZHOU, China, March 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company...
Suvoda launches Sofia, a new AI assistant to simplify management of clinical trials
From many clicks to one query, drug supply managers can more quickly access, analyze, and visualize the trial supply data they need. PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare...
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma (ndGBM), the most aggressive form of brain cancer, that...
Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director
ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner, today announced the appointment of John Chiminski and Karen Flynn as non-executive members of its Board of Directors. John will serve as Chair of the Board and EW Healthcare Partners has designated Karen...
Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics
SINGAPORE, March 5, 2025 /PRNewswire/ -- In a significant development for the clinical diagnostics landscape in Singapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to form Archerfish Precision Diagnostics Private Limited (Archerfish). This strategic union brings together two leading laboratory players with complementary expertise –...
EMFACE Surpasses 1 Million Treatments, Becoming the Fastest-Growing Non-Invasive Facial Lifting Procedure
PRAGUE, March 5, 2025 /PRNewswire/ -- EMFACE, the revolutionary non-invasive facial treatment, has reached an extraordinary milestone—becoming the fastest procedure of its kind to surpass 1 million treatments worldwide in just under two years. This achievement cements EMFACE as the leading non-invasive facial procedure uniquely designed to treat both the skin and underlying muscles for a more youthful, lifted appearance....
SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
HIGHLIGHTS Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study. Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, the SRC confirmed expansion at 8 GBq...
Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance
Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to $30.6 million in 2024 Cash and short-term assets of $84.8 million as of December 31, 2024 Provides first quarter and full year 2025 guidance Projects full year 2025 revenue of $73 million to $85 million, driven by the strong launch of IM8 Health CHARLOTTE, N.C.,...
SanyouBio Launches 73 Whole-Series Bispecific Reference Antibody Products, Facilitating New Breakthroughs in Bispecific Drug Development
SHANGHAI, March 5, 2025 /PRNewswire/ -- SanyouBio announced today the official launch of 73 whole-series bispecific antibody reference products, covering globally approved and representative clinical-stage bispecific antibody drugs. The launch of this product series will provide robust support for the development of bispecific antibody drugs, helping to overcome critical challenges in drug development. The development of bispecific antibody drugs...
The Laughing Cow – Southeast Asia Region Wins Prestigious Brand of Asia 2024-25 Award
SINGAPORE, March 5, 2025 /PRNewswire/ -- The Laughing Cow has been honored with the Prestigious Brands of Asia 2024-25 award in the FMCG - Cheese category. This recognition, presented at the Global Business Symposium hosted by Herald Global & ERTC Media in Bangkok, Thailand, was bestowed after an intensive screening process. The recognition is a testament to The Laughing Cow's remarkable...
